Prognostic value of dipyridamole technetium-99m sestamibi myocardial tomography in patients with stable chest pain who are unable to exercise

Henry G. Stratmann, Beaver R. Tamesis, Liwa T. Younis, Mark D. Wittry, Donald D Miller

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Unlike dipyridamole testing with thallium-201, the ability of technetium-99m sestamibi (MIBI) myocardial imaging to evaluate risk of later cardiac events has not been established. In this study, the prognostic value of dipyridamole MIBI myocardial tomography (same-day, rest-stress protocol) was assessed in 534 patients with stable chest pain consistent with angina pectoris. During follow-up (mean 13 ± 5 months), 58 patients (11%) had a major cardiac event-nonfatal myocardial infarction (n = 14) or cardiac death (n = 44). A history of congestive heart failure, prior myocardial infarction or diabetes mellitus, and either a reversible or fixed myocardial perfusion defect on MIBI scans were univariate and multivariate predictors of increased cardiac risk. Cardiac events occurred in 2% of patients with normal MIBI scans, compared with 15% with abnormal scans, 17% with reversible perfusion defects and 16% with fixed defects (all p <0.01). Relative risks (univariate Cox analysis) associated with an abnormal MIBI scan, a reversible perfusion defect and a fixed defect were 8.4 (95% confidence interval [Cl] 2.6 to 26.8), 1.9 (95% Cl 1.1 to 3.2) and 2.4 (95% Cl 1.4 to 4.3), respectively. Patients with any kind of perfusion abnormality (reversible or fixed) had a significantly lower cardiac event free survival than those with normal scans (all p <0.0001). It is concluded that, as with thallium-201 myocardial scintigraphy, a normal MIBI scan is associated with low cardiac risk, whereas dipyridamole-induced myocardial perfusion defects identify patients with significantly increased risk.

Original languageEnglish (US)
Pages (from-to)647-652
Number of pages6
JournalThe American Journal of Cardiology
Volume73
Issue number9
DOIs
StatePublished - Apr 1 1994
Externally publishedYes

Fingerprint

Technetium Tc 99m Sestamibi
Dipyridamole
Chest Pain
Perfusion
Tomography
Exercise
Thallium
Myocardial Infarction
Myocardial Perfusion Imaging
Angina Pectoris
Disease-Free Survival
Diabetes Mellitus
Heart Failure
Confidence Intervals

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Prognostic value of dipyridamole technetium-99m sestamibi myocardial tomography in patients with stable chest pain who are unable to exercise. / Stratmann, Henry G.; Tamesis, Beaver R.; Younis, Liwa T.; Wittry, Mark D.; Miller, Donald D.

In: The American Journal of Cardiology, Vol. 73, No. 9, 01.04.1994, p. 647-652.

Research output: Contribution to journalArticle

@article{7224113956264913afa4ca4939b9213d,
title = "Prognostic value of dipyridamole technetium-99m sestamibi myocardial tomography in patients with stable chest pain who are unable to exercise",
abstract = "Unlike dipyridamole testing with thallium-201, the ability of technetium-99m sestamibi (MIBI) myocardial imaging to evaluate risk of later cardiac events has not been established. In this study, the prognostic value of dipyridamole MIBI myocardial tomography (same-day, rest-stress protocol) was assessed in 534 patients with stable chest pain consistent with angina pectoris. During follow-up (mean 13 ± 5 months), 58 patients (11{\%}) had a major cardiac event-nonfatal myocardial infarction (n = 14) or cardiac death (n = 44). A history of congestive heart failure, prior myocardial infarction or diabetes mellitus, and either a reversible or fixed myocardial perfusion defect on MIBI scans were univariate and multivariate predictors of increased cardiac risk. Cardiac events occurred in 2{\%} of patients with normal MIBI scans, compared with 15{\%} with abnormal scans, 17{\%} with reversible perfusion defects and 16{\%} with fixed defects (all p <0.01). Relative risks (univariate Cox analysis) associated with an abnormal MIBI scan, a reversible perfusion defect and a fixed defect were 8.4 (95{\%} confidence interval [Cl] 2.6 to 26.8), 1.9 (95{\%} Cl 1.1 to 3.2) and 2.4 (95{\%} Cl 1.4 to 4.3), respectively. Patients with any kind of perfusion abnormality (reversible or fixed) had a significantly lower cardiac event free survival than those with normal scans (all p <0.0001). It is concluded that, as with thallium-201 myocardial scintigraphy, a normal MIBI scan is associated with low cardiac risk, whereas dipyridamole-induced myocardial perfusion defects identify patients with significantly increased risk.",
author = "Stratmann, {Henry G.} and Tamesis, {Beaver R.} and Younis, {Liwa T.} and Wittry, {Mark D.} and Miller, {Donald D}",
year = "1994",
month = "4",
day = "1",
doi = "10.1016/0002-9149(94)90927-X",
language = "English (US)",
volume = "73",
pages = "647--652",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Prognostic value of dipyridamole technetium-99m sestamibi myocardial tomography in patients with stable chest pain who are unable to exercise

AU - Stratmann, Henry G.

AU - Tamesis, Beaver R.

AU - Younis, Liwa T.

AU - Wittry, Mark D.

AU - Miller, Donald D

PY - 1994/4/1

Y1 - 1994/4/1

N2 - Unlike dipyridamole testing with thallium-201, the ability of technetium-99m sestamibi (MIBI) myocardial imaging to evaluate risk of later cardiac events has not been established. In this study, the prognostic value of dipyridamole MIBI myocardial tomography (same-day, rest-stress protocol) was assessed in 534 patients with stable chest pain consistent with angina pectoris. During follow-up (mean 13 ± 5 months), 58 patients (11%) had a major cardiac event-nonfatal myocardial infarction (n = 14) or cardiac death (n = 44). A history of congestive heart failure, prior myocardial infarction or diabetes mellitus, and either a reversible or fixed myocardial perfusion defect on MIBI scans were univariate and multivariate predictors of increased cardiac risk. Cardiac events occurred in 2% of patients with normal MIBI scans, compared with 15% with abnormal scans, 17% with reversible perfusion defects and 16% with fixed defects (all p <0.01). Relative risks (univariate Cox analysis) associated with an abnormal MIBI scan, a reversible perfusion defect and a fixed defect were 8.4 (95% confidence interval [Cl] 2.6 to 26.8), 1.9 (95% Cl 1.1 to 3.2) and 2.4 (95% Cl 1.4 to 4.3), respectively. Patients with any kind of perfusion abnormality (reversible or fixed) had a significantly lower cardiac event free survival than those with normal scans (all p <0.0001). It is concluded that, as with thallium-201 myocardial scintigraphy, a normal MIBI scan is associated with low cardiac risk, whereas dipyridamole-induced myocardial perfusion defects identify patients with significantly increased risk.

AB - Unlike dipyridamole testing with thallium-201, the ability of technetium-99m sestamibi (MIBI) myocardial imaging to evaluate risk of later cardiac events has not been established. In this study, the prognostic value of dipyridamole MIBI myocardial tomography (same-day, rest-stress protocol) was assessed in 534 patients with stable chest pain consistent with angina pectoris. During follow-up (mean 13 ± 5 months), 58 patients (11%) had a major cardiac event-nonfatal myocardial infarction (n = 14) or cardiac death (n = 44). A history of congestive heart failure, prior myocardial infarction or diabetes mellitus, and either a reversible or fixed myocardial perfusion defect on MIBI scans were univariate and multivariate predictors of increased cardiac risk. Cardiac events occurred in 2% of patients with normal MIBI scans, compared with 15% with abnormal scans, 17% with reversible perfusion defects and 16% with fixed defects (all p <0.01). Relative risks (univariate Cox analysis) associated with an abnormal MIBI scan, a reversible perfusion defect and a fixed defect were 8.4 (95% confidence interval [Cl] 2.6 to 26.8), 1.9 (95% Cl 1.1 to 3.2) and 2.4 (95% Cl 1.4 to 4.3), respectively. Patients with any kind of perfusion abnormality (reversible or fixed) had a significantly lower cardiac event free survival than those with normal scans (all p <0.0001). It is concluded that, as with thallium-201 myocardial scintigraphy, a normal MIBI scan is associated with low cardiac risk, whereas dipyridamole-induced myocardial perfusion defects identify patients with significantly increased risk.

UR - http://www.scopus.com/inward/record.url?scp=0028284907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028284907&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(94)90927-X

DO - 10.1016/0002-9149(94)90927-X

M3 - Article

VL - 73

SP - 647

EP - 652

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 9

ER -